| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection.
|
AIDS
|
2001
|
2.41
|
|
2
|
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
|
AIDS
|
2000
|
2.14
|
|
3
|
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men.
|
Am J Epidemiol
|
2000
|
2.05
|
|
4
|
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
|
AIDS
|
2001
|
2.03
|
|
5
|
HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
|
Lancet
|
1997
|
1.98
|
|
6
|
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
|
Lancet
|
1998
|
1.88
|
|
7
|
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?
|
Virology
|
1994
|
1.85
|
|
8
|
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma.
|
J Clin Microbiol
|
1996
|
1.75
|
|
9
|
Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia.
|
Thorax
|
2004
|
1.63
|
|
10
|
First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity.
|
Vaccine
|
2008
|
1.51
|
|
11
|
Estimating the efficacy of interventions to prevent mother-to-child transmission of HIV in breast-feeding populations: development of a consensus methodology.
|
Stat Med
|
2001
|
1.50
|
|
12
|
Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis.
|
J Infect Dis
|
2000
|
1.50
|
|
13
|
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
|
AIDS
|
1992
|
1.47
|
|
14
|
Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
|
AIDS
|
2001
|
1.42
|
|
15
|
Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?
|
AIDS
|
2005
|
1.41
|
|
16
|
Evaluation of different tests for the serodiagnosis of tuberculosis and the use of likelihood ratios in serology.
|
Am Rev Respir Dis
|
1993
|
1.38
|
|
17
|
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
|
AIDS
|
1998
|
1.34
|
|
18
|
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.
|
J Infect Dis
|
1999
|
1.32
|
|
19
|
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
|
AIDS
|
2000
|
1.26
|
|
20
|
Increased incidence of cancer in adult Gaucher disease in Western Europe.
|
Blood Cells Mol Dis
|
2005
|
1.19
|
|
21
|
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
|
AIDS
|
2001
|
1.18
|
|
22
|
Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium.
|
J Neurol Sci
|
1997
|
1.17
|
|
23
|
Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy.
|
Antimicrob Agents Chemother
|
1996
|
1.13
|
|
24
|
Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in The Netherlands: a survey of 30 kindreds.
|
Neurology
|
1994
|
1.02
|
|
25
|
Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection.
|
J Infect Dis
|
1994
|
1.01
|
|
26
|
Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group.
|
Clin Infect Dis
|
2000
|
1.00
|
|
27
|
Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis.
|
Arch Neurol
|
1995
|
1.00
|
|
28
|
Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
|
AIDS Res Hum Retroviruses
|
1998
|
0.99
|
|
29
|
Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients.
|
J Clin Microbiol
|
2000
|
0.98
|
|
30
|
Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy.
|
AIDS
|
1998
|
0.98
|
|
31
|
Community-acquired pathogens associated with prolonged coughing in children: a prospective cohort study.
|
Clin Microbiol Infect
|
2005
|
0.97
|
|
32
|
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
|
AIDS
|
1998
|
0.96
|
|
33
|
Human herpesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997): analysis of seroconversions to ORF65 and ORF73.
|
Proc Natl Acad Sci U S A
|
2000
|
0.94
|
|
34
|
Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method.
|
Vaccine
|
2006
|
0.90
|
|
35
|
Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study.
|
Prostaglandins Leukot Essent Fatty Acids
|
2004
|
0.89
|
|
36
|
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study.
|
AIDS
|
2000
|
0.89
|
|
37
|
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
|
J Infect Dis
|
1997
|
0.89
|
|
38
|
Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.
|
J Infect Dis
|
1994
|
0.87
|
|
39
|
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
|
HIV Med
|
2004
|
0.87
|
|
40
|
The prognosis of cervical cancer associated with pregnancy: a matched cohort study.
|
Obstet Gynecol
|
1995
|
0.87
|
|
41
|
Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.
|
AIDS Res Hum Retroviruses
|
1995
|
0.85
|
|
42
|
Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients.
|
Clin Pharmacol Ther
|
1997
|
0.84
|
|
43
|
Recurrence after segmental resection for colonic Crohn's disease.
|
Br J Surg
|
2005
|
0.83
|
|
44
|
Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma.
|
Gut
|
2002
|
0.82
|
|
45
|
Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine.
|
J Neuroimmunol
|
2000
|
0.82
|
|
46
|
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
|
AIDS
|
2000
|
0.81
|
|
47
|
Free fatty acids increase hepatic glycogen content in obese males.
|
Metabolism
|
2004
|
0.80
|
|
48
|
Soluble receptors for tumor necrosis factor are markers for clinical course but not for major metabolic changes in human immunodeficiency virus infection.
|
Metabolism
|
1995
|
0.80
|
|
49
|
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
|
AIDS
|
2001
|
0.79
|
|
50
|
Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
|
J Acquir Immune Defic Syndr Hum Retrovirol
|
1995
|
0.77
|
|
51
|
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
|
Antivir Ther
|
2001
|
0.77
|
|
52
|
FFAs are not involved in regulation of gluconeogenesis and glycogenolysis in adults with uncomplicated P. falciparum malaria.
|
Am J Physiol Endocrinol Metab
|
2004
|
0.76
|
|
53
|
Gluconeogenesis and fasting in cerebral malaria.
|
Neth J Med
|
2004
|
0.76
|
|
54
|
Influence of prolonged starvation on glucose kinetics in pregnant patients infected with Plasmodium falciparum.
|
Clin Nutr
|
2004
|
0.76
|
|
55
|
A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells.
|
Vaccine
|
2006
|
0.76
|
|
56
|
Timing of human immunodeficiency virus type 1 and human herpesvirus 8 infections and length of the Kaposi's sarcoma-free period in coinfected persons.
|
J Infect Dis
|
2001
|
0.75
|
|
57
|
Acute upper gastrointestinal haemorrhage.
|
Lancet
|
1996
|
0.75
|
|
58
|
Kaposi's sarcoma and human herpesvirus 8 infection do not protect HIV-1 infected homosexual men from AIDS dementia complex.
|
AIDS
|
2001
|
0.75
|
|
59
|
Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
|
J Acquir Immune Defic Syndr Hum Retrovirol
|
1996
|
0.75
|
|
60
|
A sensitive cell-based assay for the detection of residual infectious West Nile virus.
|
Vaccine
|
2007
|
0.75
|
|
61
|
Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients.
|
AIDS
|
1999
|
0.75
|
|
62
|
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
|
Ned Tijdschr Geneeskd
|
2001
|
0.75
|
|
63
|
Baseline assessments in amyotrophic lateral sclerosis trials.
|
J Neurol Sci
|
1995
|
0.75
|
|
64
|
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
|
Ned Tijdschr Geneeskd
|
1998
|
0.75
|
|
65
|
The relationship between glucose production and plasma glucose concentration in children with falciparum malaria.
|
Trans R Soc Trop Med Hyg
|
1997
|
0.75
|
|
66
|
Mortality risk stratification in amyotrophic lateral sclerosis.
|
J Neurol Sci
|
1995
|
0.75
|